TGA

Manufacturers must evaluate their products against the new thresholds and update their risk management plans (RMPs) and risk-based monitoring protocols if any exceed the limits.

Regulatory teams must prepare for and implement processes for increased public disclosures and reporting obligations regarding medical device safety data in Australia.

Sponsors and investigators must develop an implementation plan for the ISO 14155:2026 standard and maintain records for review during TGA inspections, ensuring alignment with updated safety monitoring obligations.

Manufacturers must generate and maintain scientific, engineering, and clinical evidence demonstrating that their devices meet the Essential Principles for Safety and Performance.

Confirm child is 24 months or older before administering FluMist; review Product Information; verify patient age against indication.

Stop using affected batches; return to place of purchase for full refund.

Stop using and dispose of Pharmatech MK-677 capsules immediately; consult a healthcare professional if concerned.

Consumers must stop taking the product immediately and return remaining capsules to a pharmacy for safe disposal.

Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.

Regulatory teams must update product labeling to reflect the new indication and assess signal management considerations for capivasertib.

Health professionals and stakeholders should review the safety signals linked to CAROTONE products in their signal management processes.

Ensure compliance checks are reinforced in the inspection readiness processes to account for potential non-compliance surrounding product imports.

Ongoing investigations into unlawful vaping products are expected to result in further enforcement actions, including additional seizures and potential penalties for non-compliance with the Therapeutic Goods Act.

Regulatory intelligence workflows should address this enforcement action as part of ongoing compliance monitoring regarding the sale and promotion of unapproved therapeutic goods.

Organizations must enhance signal management processes to track and report adverse events related to Melanotan II products, ensuring compliance with safety regulations.

Ensure all patient implant cards are updated to include full UDI information in the mandated formats by the specified timeline to comply with TGA regulations.

Companies must implement a strategy to upgrade from Windows 10 to Windows 11 and ensure compliance with essential safety principles, including notifying customers about potential vulnerabilities.

Stakeholders are encouraged to utilize the provided e-learning modules to improve their inspection readiness and compliance with GCP standards in Australia.

Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.

Tga update requires triage for Label Governance, Signal Validation, Risk Management; confirm local obligations and document follow-up actions.

Sponsors and MAHs must replace the 2021 form with the new 2026 approved form for all six-monthly reports on unapproved therapeutic goods supplied under SAS and CTA schemes.

Sponsors must prepare for increased costs tied to the submission and maintenance of products on the ARTG which will impact their regulatory budget planning and compliance processes.

Review and implement the TGA checklist for all psychiatrist prescribers of MDMA/psilocybine; update ICSR workflows to capture adverse events as per checklist requirements.

Review the consultation document and consider submitting feedback by 2026-07-31. Monitor for final regulatory changes affecting radiopharmaceutical safety monitoring and compliance.

1) Add/confirm the TGA 'medical device post-market monitoring and safety updates' page as a tracked regulatory intelligence source for routine review. 2) Cross-check internal Australia device vigilance SOPs/work instructions against TGA guidance on sponsor/manufacturer post-market responsibilities and document any gaps for CAPA/change control as needed.

Regulatory Intelligence leads should initiate monitoring of feedback and prepare for potential regulatory adjustments related to the specified substances.